Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Thermo Fisher Scientific Launches Animal Origin-Free Gibco CTS OpTmizer One SFM to Boost Cell Therapy Manufacturing Scalability

NextEdge Admin

13 Apr 2024

2 min 21 sec

Thermo Fisher Scientific Inc. has unveiled the Gibco CTS OpTmizer One Serum-Free Medium (CTS OpTmizer One SFM), a breakthrough animal origin-free (AOF) formulation tailored for clinical and commercial cell therapy manufacturing. This innovative medium enhances scalability and performance in T cell expansion, crucial for accelerating the delivery of T cell therapies to patients.

CTS OpTmizer One SFM is a ready-to-use, one-part medium, streamlining manufacturing processes from development to commercialization while ensuring consistent performance. It fosters high cell viability, improved growth, and preserves early memory T cell characteristics. By eliminating animal-origin components, it minimizes contamination risks, enhancing reliability and safety.

This advancement enables rapid expansion of less-differentiated T cells, reducing treatment timelines, manufacturing costs, and improving therapeutic efficacy. Its compatibility with various culture vessels and scales, including G-Rex plates and bioreactors, offers flexibility for both autologous and allogeneic workflows.

Available in multiple volumes, CTS OpTmizer One SFM is compatible with closed automated instruments, further streamlining manufacturing processes. It complements Thermo Fisher’s Gibco Cell Therapy Systems (CTS) portfolio, known for its flexibility, efficiency, and scalability across the cell therapy manufacturing workflow.

Thermo Fisher Scientific’s commitment to advancing science is underscored by its mission to empower customers in making the world healthier, cleaner, and safer. With a robust revenue exceeding $40 billion annually, Thermo Fisher continues to lead in serving the scientific community, offering comprehensive support from research to commercialization in life sciences, diagnostics, and therapy development.